Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Daiichi Sankyo
Fish and Richardson

Generated: December 10, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,148,359

« Back to Dashboard

Which drugs does patent 7,148,359 protect, and when does it expire?

Patent 7,148,359 protects VIEKIRA XR, VIEKIRA PAK (COPACKAGED), KALETRA, NORVIR, and TECHNIVIE, and is included in five NDAs. There have been zero Paragraph IV challenges on Kaletra and Norvir

Protection for KALETRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 7,148,359

Title:Polymorph of a pharmaceutical
Abstract:A new crystalline polymorph of ritonavir and methods for its use and preparation are disclosed.
Inventor(s): Chemburkar; Sanjay R. (Gurnee, IL), Patel; Ketan (Arlington Heights, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:11/122,300
Patent Claim Types:
see list of patent claims

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Abbvie IncVIEKIRA XRdasabuvir sodium; ombitasvir; paritaprevir; ritonavirTABLET, EXTENDED RELEASE;ORAL208624-001Jul 22, 2016RXYesYes► Subscribe► Subscribe► SubscribeY
Abbvie IncVIEKIRA PAK (COPACKAGED)dasabuvir sodium ; ombitasvir; paritaprevir; ritonavirTABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► SubscribeY
AbbvieKALETRAlopinavir; ritonavirTABLET;ORAL021906-002Nov 9, 2007RXYesNo► Subscribe► Subscribe► SubscribeY
AbbvieKALETRAlopinavir; ritonavirTABLET;ORAL021906-001Oct 28, 2005RXYesYes► Subscribe► Subscribe► SubscribeY
AbbvieNORVIRritonavirTABLET;ORAL022417-001Feb 10, 2010ABRXYesYes► Subscribe► Subscribe► SubscribeY
Abbvie IncTECHNIVIEombitasvir; paritaprevir; ritonavirTABLET;ORAL207931-001Jul 24, 2015RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,148,359

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,894,171 Polymorph of a pharmaceutical► Subscribe
8,674,112Polymorph of a pharmaceutical► Subscribe
8,193,367Polymorph of a pharmaceutical► Subscribe
9,255,092Polymorph of a pharmaceutical► Subscribe
7,659,405Polymorph of a pharmaceutical► Subscribe
7,183,416Polymorph of a pharmaceutical► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Farmers Insurance
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: